Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2246994/bristol-myers-squibb-bmy-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246994
Mar 27, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2255656/bristol-myers-squibb-bmy-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2255656
Apr 15, 2024 - Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811
Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
0
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
https://www.zacks.com/stock/news/2194725/biotech-stock-roundup-exel-partners-rcus-for-study-phvs-eypt-gain-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2194725
Dec 07, 2023 - Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.
0
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
https://www.zacks.com/stock/news/2196867/bristol-myers-bmy-partners-with-systimmune-for-oncology-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196867
Dec 12, 2023 - Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
0
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201005
Dec 21, 2023 - With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-1-2-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202697
Dec 27, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
0